With the surging enthusiasm for immunotherapy for other solid malignancies, immune therapeutic targeting of STAT3 is a compelling strategy for modulating tumor-mediated immune suppression, especially for a cancer like GBM that has in general not been responsive to immune checkpoint inhibitor monotherapies [83,84]. This evidence concerns the gene STAT3 and glioblastoma.